Content
01/05/2021
Philadelphia, PA USA
Aro Biotherapeutics
completed $88 million Series A Round funding. Investors include
Northpond Ventures (lead), Cowen Healthcare Investments (lead), BioMotiv, BVF Partners, HealthCap, Johnson & Johnson Impact Ventures.
About
Unlocking the Potential of Genetic Medicines
Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
